Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

In a randomized trial involving children with severe systemic juvenile idiopathic arthritis, the anti–interleukin-6 receptor antibody tocilizumab was effective (response rate, 85% with tocilizumab vs. 24% with placebo). Adverse events included serious infections and neutropenia. Systemic juvenile id...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2012-12, Vol.367 (25), p.2385-2395
Hauptverfasser:	De Benedetti, Fabrizio, Brunner, Hermine I, Ruperto, Nicolino, Kenwright, Andrew, Wright, Stephen, Calvo, Inmaculada, Cuttica, Ruben, Ravelli, Angelo, Schneider, Rayfel, Woo, Patricia, Wouters, Carine, Xavier, Ricardo, Zemel, Lawrence, Baildam, Eileen, Burgos-Vargas, Ruben, Dolezalova, Pavla, Garay, Stella M, Merino, Rosa, Joos, Rik, Grom, Alexei, Wulffraat, Nico, Zuber, Zbigniew, Zulian, Francesco, Lovell, Daniel, Martini, Alberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Arthritis, Juvenile - blood Arthritis, Juvenile - drug therapy Biological and medical sciences Child Child, Preschool Clinical trials Cytokines Data processing Diseases of the osteoarticular system Double-Blind Method Drug Therapy, Combination Female General aspects Glucocorticoids - therapeutic use Humans Infections - chemically induced Inflammatory joint diseases Male Medical sciences Methotrexate - therapeutic use Neutropenia - chemically induced Pediatrics Receptors, Interleukin-6 - antagonists & inhibitors Rheumatology Statistical analysis Transaminases - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!